Portal de Periódicos da CAPES

5‐hydroxytryptamine (5‐HT, serotonin) and Parkinson's disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy

2002; Wiley; Volume: 9; Issue: s3 Linguagem: Inglês

10.1046/j.1468-1331.9.s3.1.x

1468-1331

Sarah Leigh Nicholson, Jonathan M. Brotchie,

Neurological disorders and treatments

While Parkinson's disease is undoubtedly a disorder with a primary pathology of dopamine neuronal loss, that loss of dopamine and subsequent dopamine replacement therapy leads to imbalances in many non-dopaminergic transmitter systems, including 5-hydroxytryptamine (5-HT). Recent advances in understanding the role of 5-HT in parkinsonism and the generation of side-effects of dopamine replacement therapy (e.g. wearing-off and levodopa-induced dyskinesia) have identified 5-HT1A, 5-HT1B and 5-HT2C receptors as potential therapeutic targets in Parkinson's disease.